MXPA04012491A - Estratrienos 9-alfa-sustituidos como estrogenos selectivamente activos. - Google Patents

Estratrienos 9-alfa-sustituidos como estrogenos selectivamente activos.

Info

Publication number
MXPA04012491A
MXPA04012491A MXPA04012491A MXPA04012491A MXPA04012491A MX PA04012491 A MXPA04012491 A MX PA04012491A MX PA04012491 A MXPA04012491 A MX PA04012491A MX PA04012491 A MXPA04012491 A MX PA04012491A MX PA04012491 A MXPA04012491 A MX PA04012491A
Authority
MX
Mexico
Prior art keywords
estra
trien
vinyl
diol
carbon atoms
Prior art date
Application number
MXPA04012491A
Other languages
English (en)
Spanish (es)
Inventor
Hillisch Alexander
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA04012491A publication Critical patent/MXPA04012491A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA04012491A 2002-06-11 2003-06-11 Estratrienos 9-alfa-sustituidos como estrogenos selectivamente activos. MXPA04012491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
PCT/EP2003/006172 WO2003104253A2 (de) 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene

Publications (1)

Publication Number Publication Date
MXPA04012491A true MXPA04012491A (es) 2005-06-08

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04012491A MXPA04012491A (es) 2002-06-11 2003-06-11 Estratrienos 9-alfa-sustituidos como estrogenos selectivamente activos.

Country Status (28)

Country Link
EP (1) EP1517914B1 (enExample)
JP (1) JP4615998B2 (enExample)
KR (1) KR101006612B1 (enExample)
CN (1) CN1293090C (enExample)
AR (1) AR040188A1 (enExample)
AT (1) ATE303397T1 (enExample)
AU (1) AU2003242683B9 (enExample)
BR (1) BR0312140A (enExample)
CA (1) CA2486495C (enExample)
CR (1) CR10289A (enExample)
CU (1) CU23414B7 (enExample)
DE (2) DE10226326A1 (enExample)
DK (1) DK1517914T3 (enExample)
EA (1) EA008442B1 (enExample)
EC (1) ECSP055530A (enExample)
ES (1) ES2248770T3 (enExample)
HR (1) HRP20050009B1 (enExample)
IL (1) IL165321A (enExample)
MX (1) MXPA04012491A (enExample)
NO (1) NO329563B1 (enExample)
PE (1) PE20040613A1 (enExample)
PL (1) PL209910B1 (enExample)
RS (1) RS50878B (enExample)
TW (1) TWI286140B (enExample)
UA (1) UA78062C2 (enExample)
UY (1) UY27844A1 (enExample)
WO (1) WO2003104253A2 (enExample)
ZA (1) ZA200500217B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1689410B1 (en) * 2003-11-26 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CA3109978A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
AU5834101A (en) * 2000-04-12 2001-10-23 Schering Ag 8ss-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
CA2486495C (en) 2011-04-19
TWI286140B (en) 2007-09-01
PL373090A1 (en) 2005-08-08
HRP20050009B1 (hr) 2013-07-31
ES2248770T3 (es) 2006-03-16
AU2003242683A1 (en) 2003-12-22
NO20050127L (no) 2005-03-11
WO2003104253A2 (de) 2003-12-18
ZA200500217B (en) 2006-03-29
DE10226326A1 (de) 2004-01-15
CN1659181A (zh) 2005-08-24
JP4615998B2 (ja) 2011-01-19
CN1293090C (zh) 2007-01-03
KR20050009745A (ko) 2005-01-25
DK1517914T3 (da) 2006-01-16
AU2003242683B2 (en) 2009-07-02
NO20050127D0 (no) 2005-01-10
NO329563B1 (no) 2010-11-15
ECSP055530A (es) 2005-03-10
HRP20050009A2 (en) 2005-04-30
PE20040613A1 (es) 2004-12-01
KR101006612B1 (ko) 2011-01-10
HK1081203A1 (en) 2006-05-12
PL209910B1 (pl) 2011-11-30
TW200407331A (en) 2004-05-16
UA78062C2 (en) 2007-02-15
IL165321A (en) 2009-08-03
CR10289A (es) 2008-11-26
EP1517914A2 (de) 2005-03-30
CU23414B7 (es) 2009-09-08
UY27844A1 (es) 2003-12-31
CA2486495A1 (en) 2003-12-18
DE50301116D1 (de) 2005-10-06
RS50878B (sr) 2010-08-31
RS107004A (sr) 2006-10-27
EA008442B1 (ru) 2007-06-29
AU2003242683B9 (en) 2009-08-27
AR040188A1 (es) 2005-03-16
JP2005533053A (ja) 2005-11-04
EP1517914B1 (de) 2005-08-31
BR0312140A (pt) 2005-04-05
WO2003104253A3 (de) 2004-09-16
EA200401544A1 (ru) 2005-06-30
ATE303397T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
US7414043B2 (en) 9-α-substituted estratrienes as selectively active estrogens
EP1169336B1 (en) Ent-steroids as selectively active estrogens
US7378404B2 (en) 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens
CA2359660A1 (en) 16-hydroxyestratrienes as selective estrogens
CA2486495C (en) 9-alpha-substituted estratrienes as selectively active estrogens
PT1226155E (pt) 18-nor-esteróides como estrogénios selectivamente activos
ES2393942T3 (es) 16,ALFA-FLUORO-ESTRATIENOS 8-BETA- sustituidos en calidad de estrógenos selectivamente activos
US20060270845A1 (en) 16-Hydroxyestratrienes as selectively active estrogens
NZ536882A (en) 9-Alpha-substituted estratrienes as selectively active estrogens
HK1142612A (en) 8-beta-substituted estratrienes as selectively active estrogens
AU2004201405A1 (en) Ent-Steroids as selectively active estrogens

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration
HC Change of company name or juridical status